Open-access OCTA tools showed similar reliability, but different vessel density values in glaucoma; researchers advise using one tool consistently.
|Articles|May 19, 2020
Week 9 of COVID-19 at Dr. Ben Casella's practice
Author(s)Benjamin P. Casella, OD, FAAO
Advertisement
Chief Optometric Editor Ben Casella, OD, FAAO, checks in during Week 9 of the pandemic. His office is seeing about 1 patient per hour, and he has moved to wearing scrubs in the office. Check out the rest of his update!
Advertisement
Related to this article
Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier timepoints.
CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.
Drs Bryce St. Clair and Behrad Garmsiri explain how they build trust, improve health literacy, and destigmatize future interventions for patients with AMD.
Diana Canto-Sims, OD, introduces the second guest of Season 2, Raphael Rostenne, who will be discussing AI-assisted front desk management.
Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.
Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness.
From dry eye to GLP-1s, this year's conference brought a variety of insights from key experts in optometry.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
More than monitoring: Using AMD visits to promote healthy vision aging
2
Study: OCTA analysis tools report different macular vessel density values for glaucoma
3
FDA approves Brytly eye drops for ocular redness relief lasting up to 12 hours
4
Brepocitinib for noninfectious uveitis meets all phase 3 trial end points
5